Kestra Medical Technologies Ltd. (KMTS) Price & Analysis

Compare

16 Followers

KMTS Stock Chart & Stats

$22.29

Market closed

$22.29

Day’s Range― - ―

52-Week Range$13.25 - $30.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)310.69K

Market Cap

$1.34B

Enterprise Value$1.14B

Total Cash (Recent Filing)$175.42M

Total Debt (Recent Filing)$2.93M

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Apr 20, 2026

EPS Estimate

-0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.64

Shares Outstanding58,349,052

10 Day Avg. Volume502,173

30 Day Avg. Volume310,694

Financial Highlights & Ratios

PEG Ratio-0.69

Price to Book (P/B)-5.17

Price to Sales (P/S)38.89

P/FCF Ratio-12.76

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue15.38

Enterprise Value/Gross Profit33.15

Enterprise Value/Ebitda-9.86

Forecast

1Y Price Target

$29.00

Price Target Upside30.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-2.31

Revenue Forecast (FY)$90.94M

Bulls Say, Bears Say

Bulls Say

Financial Position And Margin ImprovementAnalyst notes improved gross margins and a successful capital raise that strengthen the balance sheet and provide resources to accelerate commercialization and support margin expansion.

Guideline Revision And Clinical AdoptionAnalyst highlights that stronger guideline classification tied to recent clinical evidence could prompt clinicians to prescribe wearable defibrillators more routinely, creating meaningful upside to adoption and revenue.

Partnership And Remote Monitoring ExpansionAnalyst points to the Biobeat Technologies partnership as a catalyst to broaden remote monitoring capabilities and open new channels for device deployment and recurring services.

Bears Say

Adoption And Reimbursement SensitivityAnalyst highlights that broader market growth depends on clinician prescribing behavior and reimbursement pathways, which could keep stock performance volatile if adoption lags despite positive studies.

Dependence On Guideline-driven GrowthAnalyst cautions that significant upside relies on guideline updates not yet reflected in consensus estimates, raising downside risk if updates are delayed or not adopted.

Timing Uncertainty Of Guideline ChangesAnalyst warns that uncertainty about when guideline committees will act creates execution risk and could delay the expected market acceleration for wearable defibrillators.

Kestra Medical Technologies Ltd. News

Kestra Medical price target lowered to $24 from $27 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Kestra Medical (KMTS) to $24 from $27 and keeps a...

2M ago

KMTS

Kestra Medical announces strategic collaboration with Biobeat Technologies

Kestra Medical (KMTS) Technologies announced a strategic collaboration with Biobeat Technologies to expand diagnostic insight for patients prescribed...

2M ago

KMTS

Kestra Medical price target raised to $27 from $25 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Kestra Medical (KMTS) to $27 from $25 and keeps a...

2M ago

KMTS

Kestra Medical price target raised to $25 from $22 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Kestra Medical (KMTS) to $25 from $22 and keeps a...

3M ago

KMTS

Kestra Medical Technologies Reports Strong Earnings Growth

Kestra Medical Technologies Ltd. (($KMTS)) has held its Q2 earnings call. Read on for the main highlights of...

3M ago

KMTS

Kestra Medical price target raised to $30 from $28 at Stifel

Stifel raised the firm’s price target on Kestra Medical (KMTS) to $30 from $28 and keeps a Buy...

3M ago

KMTS

Morning Movers: Cannabis stocks higher after reports of reclassification

Stock futures are mixed this morning, reflecting a rotation out of technology names and into more cyclical and...

3M ago

Kestra Medical price target raised to $28 from $27 at Wells Fargo

Wells Fargo raised the firm’s price target on Kestra Medical (KMTS) to $28 from $27 and keeps an...

3M ago

KMTS

Kestra Medical price target raised to $30 from $27 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Kestra Medical (KMTS) to $30 from $27...

3M ago

KMTS

Kestra Medical Technologies: Strong Financial Performance and Market Leadership Drive Buy Rating

Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Kestra Medical Technologies Ltd.....

3M ago

KMTS

Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%

In the opening hour of the evening session, U.S. equity futures are mixed, with S&P e-minis flat, Dow...

3M ago

Kestra Medical reports Q2 EPS (64c), consensus (57c)

Reports Q2 revenue $22.57M, consensus $20.96M. “Kestra delivered another strong quarter of financial performance, generating revenue growth of...

3M ago

KMTS

Kestra Medical Technologies Ltd. (KMTS) Q2 Earnings Cheat Sheet

Kestra Medical Technologies Ltd. (KMTS) is scheduled to report 2nd quarter earnings on 12/11/2025, after the market closes....

3M ago

KMTS

Kestra Medical Raises $148.4 Million in Public Offering

The latest announcement is out from Kestra Medical Technologies Ltd. ( ($KMTS) ). On December 4, 2025, Kestra...

3M ago

KMTS

KMTS FAQ

What was Kestra Medical Technologies Ltd.’s price range in the past 12 months?

Kestra Medical Technologies Ltd. lowest stock price was $13.25 and its highest was $30.00 in the past 12 months.

What is Kestra Medical Technologies Ltd.’s market cap?

Kestra Medical Technologies Ltd.’s market cap is $1.34B.

When is Kestra Medical Technologies Ltd.’s upcoming earnings report date?

Kestra Medical Technologies Ltd.’s upcoming earnings report date is Apr 20, 2026 which is in 45 days.

How were Kestra Medical Technologies Ltd.’s earnings last quarter?

Kestra Medical Technologies Ltd. released its earnings results on Dec 11, 2025. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.594 by -$0.046.

Is Kestra Medical Technologies Ltd. overvalued?

According to Wall Street analysts Kestra Medical Technologies Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kestra Medical Technologies Ltd. pay dividends?

Kestra Medical Technologies Ltd. does not currently pay dividends.

What is Kestra Medical Technologies Ltd.’s EPS estimate?

Kestra Medical Technologies Ltd.’s EPS estimate is -0.6.

How many shares outstanding does Kestra Medical Technologies Ltd. have?

Kestra Medical Technologies Ltd. has 58,349,052 shares outstanding.

What happened to Kestra Medical Technologies Ltd.’s price movement after its last earnings report?

Kestra Medical Technologies Ltd. reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.594. Following the earnings report the stock price went up 5.058%.

Which hedge fund is a major shareholder of Kestra Medical Technologies Ltd.?

Currently, no hedge funds are holding shares in KMTS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kestra Medical Technologies Ltd. Stock Smart Score

Neutral

Company Description

Kestra Medical Technologies Ltd.

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.

Kestra Medical Technologies Ltd. (KMTS) Earnings & Revenues

Historic Earnings Reports

KMTS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant growth in revenue and gross margin, supported by positive clinical study outcomes and an expanded sales force. However, the company continues to face challenges with net losses and operating expenses, along with the underpenetrated WCD market. Overall, the positive aspects of revenue growth and clinical validation outweigh the negatives.View all KMTS earnings summaries

KMTS Stock 12 Month Forecast

Average Price Target

$29.00

▲(30.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","33":"$33","18.75":"$18.75","23.5":"$23.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.75,23.5,28.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,25.53846153846154,26.076923076923077,26.615384615384617,27.153846153846153,27.692307692307693,28.23076923076923,28.76923076923077,29.307692307692307,29.846153846153847,30.384615384615383,30.923076923076923,31.46153846153846,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,25.307692307692307,25.615384615384617,25.923076923076923,26.23076923076923,26.53846153846154,26.846153846153847,27.153846153846153,27.46153846153846,27.76923076923077,28.076923076923077,28.384615384615387,28.692307692307693,{"y":29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,24.923076923076923,24.846153846153847,24.76923076923077,24.692307692307693,24.615384615384617,24.53846153846154,24.46153846153846,24.384615384615383,24.307692307692307,24.23076923076923,24.153846153846153,24.076923076923077,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.99,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >